文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

异源 ChAdOx1-nCoV-19 初免和 BNT162b2 或 mRNA-1273 加强与同源 COVID-19 疫苗方案的免疫原性和反应原性比较。

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.

机构信息

Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany.

Department of Internal Medicine IV, Saarland University, Homburg, Germany.

出版信息

Nat Commun. 2022 Aug 11;13(1):4710. doi: 10.1038/s41467-022-32321-0.

DOI:10.1038/s41467-022-32321-0
PMID:35953492
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9366133/
Abstract

Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and homologous vaccination strategies in a convenience cohort of 331 healthy individuals. All regimens induce immunity to the vaccine antigen. Immunity after vaccination with ChAdOx1-nCoV-19 followed by either BNT162b2 (n = 66) or mRNA-1273 (n = 101) is equivalent to or more pronounced than homologous mRNA-regimens (n = 43 BNT162b2, n = 59 mRNA-1273) or homologous ChAdOx1-nCoV-19 vaccination (n = 62). We note highest levels of spike-specific CD8 T-cells following both heterologous regimens. Among mRNA-containing combinations, spike-specific CD4 T-cell levels in regimens including mRNA-1273 are higher than respective combinations with BNT162b2. Polyfunctional T-cell levels are highest in regimens based on ChAdOx1-nCoV-19-priming. All five regimens are well tolerated with most pronounced reactogenicity upon ChAdOx1-nCoV-19-priming, and ChAdOx1-nCoV-19/mRNA-1273-boosting. In conclusion, we present comparative analyses of immunogenicity and reactogenicity for heterologous vector/mRNA-boosting and homologous mRNA-regimens.

摘要

比较同源和异源 SARS-CoV-2 疫苗方案的免疫原性和反应原性将为优化疫苗策略提供信息。在这里，我们分析了 331 名健康个体的便利队列中异源和同源疫苗方案后的体液和细胞免疫反应。所有方案均诱导疫苗抗原的免疫。用 ChAdOx1-nCoV-19 进行疫苗接种后再接种 BNT162b2（n=66）或 mRNA-1273（n=101）的免疫与同源 mRNA 方案（n=43 BNT162b2，n=59 mRNA-1273）或同源 ChAdOx1-nCoV-19 疫苗接种（n=62）相当或更明显。我们注意到两种异源方案后刺突特异性 CD8 T 细胞水平最高。在含有 mRNA 的组合中，包括 mRNA-1273 的方案中的刺突特异性 CD4 T 细胞水平高于分别与 BNT162b2 的组合。基于 ChAdOx1-nCoV-19 引发的方案中多功能 T 细胞水平最高。所有五种方案均具有良好的耐受性，在 ChAdOx1-nCoV-19 引发和 ChAdOx1-nCoV-19/mRNA-1273 增强时反应原性最明显。总之，我们对异源载体/mRNA 增强和同源 mRNA 方案的免疫原性和反应原性进行了比较分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/40d03a654e4a/41467_2022_32321_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/de097da060eb/41467_2022_32321_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/b0121c8cfc90/41467_2022_32321_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/ce4a784d44cc/41467_2022_32321_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/e1bc4cbab6ee/41467_2022_32321_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/40d03a654e4a/41467_2022_32321_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/de097da060eb/41467_2022_32321_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/b0121c8cfc90/41467_2022_32321_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/ce4a784d44cc/41467_2022_32321_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/e1bc4cbab6ee/41467_2022_32321_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/40d03a654e4a/41467_2022_32321_Fig5_HTML.jpg

相似文献

[1]
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.

Nat Commun. 2022-8-11

[2]
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.

Lancet Respir Med. 2021-11

[3]
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

EBioMedicine. 2022-1

[4]
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.

Nat Med. 2021-9

[5]
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.

Front Immunol. 2022

[6]
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Lancet Respir Med. 2022-11

[7]
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.

Influenza Other Respir Viruses. 2024-5

[8]
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.

Allergy. 2022-8

[9]
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.

Hum Vaccin Immunother. 2022-11-30

[10]
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.

Nature. 2021-12

引用本文的文献

[1]
Vaccination Strategies: Mixing Paths Versus Matching Tracks.

Vaccines (Basel). 2025-3-13

[2]
Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis.

Front Immunol. 2025-2-13

[3]
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.

Front Immunol. 2025-1-22

[4]
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial.

Life Metab. 2023-5-10

[5]
The Global Burden of Absenteeism Related to COVID-19 Vaccine Side Effects Among Healthcare Workers: A Systematic Review and Meta-Analysis.

Vaccines (Basel). 2024-10-19

[6]
Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?

Heliyon. 2024-8-10

[7]
Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study.

Sci Rep. 2024-4-18

[8]
SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals.

Nat Commun. 2024-4-9

[9]
The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.

J Virol. 2024-4-16

[10]
Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study.

Vaccine X. 2024-1-20

本文引用的文献

[1]
Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses.

Nat Immunol. 2022-3

[2]
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.

Lancet. 2022-2-5

[3]
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Lancet. 2022-1-1

[4]
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.

Lancet. 2021-12-18

[5]
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.

Lancet Reg Health Eur. 2021-12

[6]
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.

Nature. 2021-12

[7]
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients.

Am J Transplant. 2021-12

[8]
Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination.

Cell Mol Immunol. 2021-10

[9]
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.

BMJ. 2021-8-20

[10]
SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.

Lancet. 2021-9-18

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索